FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385185722> ?p ?o ?g. }

• W4385185722 endingPage "4330" @default.
• W4385185722 startingPage "4319" @default.
• W4385185722 abstract "Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC." @default.
• W4385185722 created "2023-07-25" @default.
• W4385185722 creator A5004148771 @default.
• W4385185722 creator A5031779188 @default.
• W4385185722 creator A5035000626 @default.
• W4385185722 creator A5038377968 @default.
• W4385185722 creator A5042300545 @default.
• W4385185722 creator A5051602756 @default.
• W4385185722 creator A5057812298 @default.
• W4385185722 creator A5060176696 @default.
• W4385185722 creator A5067162282 @default.
• W4385185722 creator A5071888326 @default.
• W4385185722 creator A5088692088 @default.
• W4385185722 creator A5089453603 @default.
• W4385185722 date "2023-07-24" @default.
• W4385185722 modified "2023-10-14" @default.
• W4385185722 title "Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma" @default.
• W4385185722 cites W1597336200 @default.
• W4385185722 cites W1939365747 @default.
• W4385185722 cites W1946441967 @default.
• W4385185722 cites W1968893400 @default.
• W4385185722 cites W1983692618 @default.
• W4385185722 cites W1992995822 @default.
• W4385185722 cites W2002689409 @default.
• W4385185722 cites W2013316743 @default.
• W4385185722 cites W2039011000 @default.
• W4385185722 cites W2039675196 @default.
• W4385185722 cites W2048253455 @default.
• W4385185722 cites W2065215232 @default.
• W4385185722 cites W2084355281 @default.
• W4385185722 cites W2088110734 @default.
• W4385185722 cites W2101653483 @default.
• W4385185722 cites W2111895881 @default.
• W4385185722 cites W2114015218 @default.
• W4385185722 cites W2115481097 @default.
• W4385185722 cites W2117089720 @default.
• W4385185722 cites W2118323175 @default.
• W4385185722 cites W2130464657 @default.
• W4385185722 cites W2139325323 @default.
• W4385185722 cites W2141047548 @default.
• W4385185722 cites W2141067132 @default.
• W4385185722 cites W2142401479 @default.
• W4385185722 cites W2151279036 @default.
• W4385185722 cites W2156569937 @default.
• W4385185722 cites W2393943335 @default.
• W4385185722 cites W2462485532 @default.
• W4385185722 cites W2509039973 @default.
• W4385185722 cites W2517354454 @default.
• W4385185722 cites W2562579911 @default.
• W4385185722 cites W2600585133 @default.
• W4385185722 cites W2624883664 @default.
• W4385185722 cites W2744974851 @default.
• W4385185722 cites W2772923107 @default.
• W4385185722 cites W2900131693 @default.
• W4385185722 cites W2930582547 @default.
• W4385185722 cites W2964086043 @default.
• W4385185722 cites W2977880794 @default.
• W4385185722 cites W2999417355 @default.
• W4385185722 cites W3000405505 @default.
• W4385185722 cites W3007212572 @default.
• W4385185722 cites W3021215586 @default.
• W4385185722 cites W3021606396 @default.
• W4385185722 cites W3039982251 @default.
• W4385185722 cites W3046386493 @default.
• W4385185722 cites W3087511582 @default.
• W4385185722 cites W3100976542 @default.
• W4385185722 cites W3125078677 @default.
• W4385185722 cites W3125250662 @default.
• W4385185722 cites W3196595027 @default.
• W4385185722 cites W4281400179 @default.
• W4385185722 cites W4297459904 @default.
• W4385185722 cites W4309837641 @default.
• W4385185722 cites W4365810922 @default.
• W4385185722 cites W4377022379 @default.
• W4385185722 doi "https://doi.org/10.1021/acs.molpharmaceut.3c00453" @default.
• W4385185722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37485886" @default.
• W4385185722 hasPublicationYear "2023" @default.
• W4385185722 type Work @default.
• W4385185722 citedByCount "0" @default.
• W4385185722 crossrefType "journal-article" @default.
• W4385185722 hasAuthorship W4385185722A5004148771 @default.
• W4385185722 hasAuthorship W4385185722A5031779188 @default.
• W4385185722 hasAuthorship W4385185722A5035000626 @default.
• W4385185722 hasAuthorship W4385185722A5038377968 @default.
• W4385185722 hasAuthorship W4385185722A5042300545 @default.
• W4385185722 hasAuthorship W4385185722A5051602756 @default.
• W4385185722 hasAuthorship W4385185722A5057812298 @default.
• W4385185722 hasAuthorship W4385185722A5060176696 @default.
• W4385185722 hasAuthorship W4385185722A5067162282 @default.
• W4385185722 hasAuthorship W4385185722A5071888326 @default.
• W4385185722 hasAuthorship W4385185722A5088692088 @default.
• W4385185722 hasAuthorship W4385185722A5089453603 @default.
• W4385185722 hasBestOaLocation W43851857221 @default.
• W4385185722 hasConcept C109316439 @default.
• W4385185722 hasConcept C111798993 @default.
• W4385185722 hasConcept C121608353 @default.
• W4385185722 hasConcept C126322002 @default.
• W4385185722 hasConcept C142724271 @default.

• next